<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811783</url>
  </required_header>
  <id_info>
    <org_study_id>EL-1007-01-01</org_study_id>
    <secondary_id>1R01FD005396-01A1</secondary_id>
    <nct_id>NCT02811783</nct_id>
  </id_info>
  <brief_title>Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL</brief_title>
  <official_title>A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elorac, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elorac, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, double-blind, vehicle-controlled, randomized crossover design study will
      evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the
      treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS)
      Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is
      systemic absorption of the drug in a subset of subjects and if so, describe the range and
      mean plasma levels reached after two weeks of three time daily (TID) dosing.

      Funding Source - FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 160 subjects enrolled in the study. The study consists of a Screening Period of
      up to 7 days during which inclusion / exclusion criteria will be reviewed. Subjects meeting
      inclusion / exclusion criteria including the diagnostic criteria for MF or SS and a score of
      at least 5 on the 11-Point Numeric Rating Scale (NRS) for Pruritus will complete the one week
      Screening Period. Subjects will complete a daily diary for NRS for Pruritus scores and Sleep
      scores. At the end of the Screening Period, subjects who have a NRS for Pruritus score of at
      least 5 recorded in the diary on at least 4 of the 7 days preceding Day 0 will be eligible to
      continue. Baseline assessments will be recorded for vital signs, pruritic body surface area,
      skin integrity, PQOL, and laboratory results. The Baseline period will be followed by a 2
      week Treatment Period 1 in which subjects will be randomized to Naloxone Lotion 0.5% or
      Placebo Lotion to be applied TID for 14 days. During the 2 week Treatment Period subjects
      will complete daily diaries of NRS for Pruritis scores and Sleep scores. On Day 14 subjects
      will return to the clinic to review diaries, adverse events (AEs), concomitant medications,
      and to record body surface area for pruritus, skin integrity, PQOL, and laboratory results.
      Subjects will then enter a Washout Period for up to 56 days until the subject again scores at
      least 5 on the NRS for Pruritus on 4 consecutive or 4 of the past 7 days or 56 days pass.
      Subjects will then enter a 2 week Treatment Period 2 during which the same procedures as
      Treatment Period 1 will be performed except subjects will receive the alternate treatment to
      that assigned in Treatment Period 1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating Scale (NRS) for Pruritus</measure>
    <time_frame>Baseline and 2 Weeks</time_frame>
    <description>Change from Baseline to Day 14 in average NRS for Pruritus for each Treatment Period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis - The difference in the proportion of subjects with a meaningful clinically significant improvement at the end of the two periods.</measure>
    <time_frame>Baseline and 2 Weeks</time_frame>
    <description>The difference in the proportion of subjects with a meaningful clinically significant improvement at the end of the two periods. A clinically significant improvement is defined as an improvement of at least one category on the 4-point (none, mild, moderate, severe) Likert Scale verbal rating scale (VRS) and at least two points on the 11-point NRS for Pruritus. The NRS for Pruritus scores will be converted to VRS scores as follows for the analysis: 0=none, 1-3=mild, 4-6=moderate, and 7-10=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale for Sleep</measure>
    <time_frame>Baseline and 1 and 2 weeks</time_frame>
    <description>The change from Baseline at each week of the NRS for Sleep average score for each Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale for Pruritus</measure>
    <time_frame>Baseline and 1 week</time_frame>
    <description>The change from Baseline at Week 1 of the NRS for Pruritus average score for each Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Rating Scale (CRS) for Skin Integrity</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>The change from Baseline at Week 2 of the CRS for Skin Integrity for each Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus Quality of Life Score (PQOL)</measure>
    <time_frame>Baseline and Day 14 of each Treatment period</time_frame>
    <description>The change from Baseline in the final categorization of the PQOL at Day 14 of each Treatment Period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Mycosis Fungoides</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <condition>Sézary Syndrome</condition>
  <arm_group>
    <arm_group_label>Naloxone Hydrochloride Lotion, 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxone Hydrochloride Lotion 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Lotion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone Hydrochloride Lotion, 0.5%</intervention_name>
    <description>Topical TID for 2 weeks</description>
    <arm_group_label>Naloxone Hydrochloride Lotion, 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Lotion</intervention_name>
    <description>Topical TID for 2 weeks</description>
    <arm_group_label>Placebo Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must meet the following criteria for admission into the study:

          1. Signed informed consent has been obtained.

          2. Subject is at least 21 years of age.

          3. Diagnosis of mycosis fungoides (MF) or Sézary syndrome (SS) will be based on a
             combination of histological, clinical, and immunophenotypical criteria. The
             histological criteria will be based on skin biopsy from the most representative skin
             area. The diagnostic criteria used for each subject will be specified in the case
             report forms and the specific classification of MF or SS will be identified. The TNMB
             system will be used to classify the stage of disease (See Section 8.4 for details).

          4. Completion of the mSWAT assessment.

          5. A history of pruritus that meets following criteria:

             At Screening Day -7:

               -  present on a daily basis for greater than one month prior to Screening Day -7,

               -  NRS for Pruritus score ≥5 as rated by the subject at the Day -7 Visit. Note: If
                  the score is &lt;5 and subject is taking or has taken a medication which may be
                  affecting pruritus (e.g. systemic antihistamine or topical steroid), and if
                  Investigator and subject agree, subject may washout or continue washout of
                  medication and return for Day -7 Visit procedures after washout.

             At Baseline Period 1 Day 0:

               -  NRS for Pruritus score of at least 5 recorded in the subject diary on at least 4
                  of the 7 days preceding Baseline Period 1 Day 0.

          6. Pruritic treatment area of 5-95% of the subject's total treatable body surface area.

          7. Subject can be expected to reliably follow treatment instructions and visit schedule.

          8. Non-pregnant, non-lactating females of childbearing potential who agree to use
             medically acceptable forms of birth control (abstinence, hormonal contraceptives,
             diaphragm with spermicide, condom with spermicide, or intrauterine device) throughout
             the study or females of non-childbearing potential (surgically sterile [hysterectomy
             or bilateral tubal ligation] or post-menopausal ≥ 1 year). A negative urine pregnancy
             test must be confirmed at Baseline screening for all female subjects who are not
             post-menopausal &gt; 1 year or surgically sterile.

          9. The subject agrees not to begin any new concomitant medications during their
             participation in the study, with the exception of medications necessary to treat
             infection, and to continue any concomitant medication throughout the study.

         10. Subject has no visual or motor impairments that will make it difficult to complete the
             Daily Diary or apply the study medication.

         11. Subject is able to speak, read, and write English and agrees to participate and comply
             with the study procedures.

         12. Subject has a body mass index (BMI) between 18.5 and 30.5 kglm2 (see Appendix C, Body
             Mass Index Table) (subjects in PK subset only).

        Exclusion Criteria:

        Subjects meeting any of the following criteria will be excluded from study participation:

          1. Pregnant or lactating female.

          2. History of clinically significant heart failure.

          3. Myocardial infarction within the past six months.

          4. A history of ventricular arrhythmia requiring treatment.

          5. Any medical condition which would, in the Investigator's opinion, preclude the subject
             from successfully participating in the study.

          6. A known allergy to naloxone hydrochloride or any excipient in the formulation.

          7. Previous naloxone use for pruritus.

          8. Positive urine drug screen at Day 0 for opiates. Positive urine drug screen for
             anything other than opiates not explained, e.g., by concomitant medication, would also
             exclude the subject.

          9. Treatment with any of the following during the restricted time period prior to Day -7,
             and at any time during the study, is not allowed:

        Medication/Treatment Restriction:

        Systemic narcotic analgesics (e.g. morphine, codeine) 7 days, Topical antihistamines to any
        skin surface [e.g. Zonalon® (doxepin)] 7 days, Other investigational drugs (excluding any
        therapies for the treatment of MF or SS) 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott B Phillips, MD</last_name>
    <role>Study Director</role>
    <affiliation>Elorac, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott B Phillips, MD</last_name>
    <phone>8473628200</phone>
    <email>scott@eloracpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidi Fezatte, BS</last_name>
    <phone>8473628200</phone>
    <email>hfezatte@eloracpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Cantrell</last_name>
      <email>wcantrell@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Elmets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Stewart</last_name>
      <phone>480-301-4441</phone>
      <email>stewart.lisa@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Mangold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Golden</last_name>
      <phone>501-686-8174</phone>
      <email>cdgolden@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Bui</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>81987</phone_ext>
      <email>dbui@coh.org</email>
    </contact>
    <investigator>
      <last_name>Christiane Querfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Skoch</last_name>
      <phone>720-848-0668</phone>
      <email>matthew.skoch@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa R Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Serrano</last_name>
      <email>linda.serrano@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Joan Guitart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Petrizzo</last_name>
      <phone>312-563-4001</phone>
      <email>carmen_m_petrizzo@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Warren W Piette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Coleman</last_name>
      <phone>504-988-5135</phone>
      <email>ecoleman@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Boh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CURTIS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elvida Arias</last_name>
      <phone>617-643-5603</phone>
    </contact>
    <investigator>
      <last_name>Steven T. Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salli Fennessey</last_name>
      <phone>617-638-8261</phone>
      <email>sally.fennessey@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Debjani Sahni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Bengtson</last_name>
      <phone>612-626-8681</phone>
      <email>jeronco@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Bohjanen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Tabacchi</last_name>
      <email>mtabacchi@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Musiek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Ulerio</last_name>
      <email>gu2102@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Larisa Geskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Brown</last_name>
      <phone>919-660-9179</phone>
      <email>pamela.r.brown@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Elise A. Olsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erich Zirzow</last_name>
      <phone>216-844-7164</phone>
      <email>erich.zirzow@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Neil Korman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Leahy</last_name>
      <email>deborah.leahy@upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Villasenor-Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Dermatology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary L. Downey, RN</last_name>
      <phone>615-343-8010</phone>
      <email>mary.l.downey@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>John Zic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas South Western Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seli Dzogbeta</last_name>
      <email>seli.dzogbeta@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Wickless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auris Huen, MD</last_name>
      <phone>713-745-1113</phone>
      <email>aohuen@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Auris Huen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jerffords</last_name>
      <phone>703-970-6548</phone>
      <email>kelly.jeffords@inova.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer A DeSimone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington / Seattle Cancer Care Alliance (SCCA)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niall Curley</last_name>
      <phone>206-606-1231</phone>
      <email>ncurley8@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Michi Shinohara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>Mycosis Fungoides</keyword>
  <keyword>CTCL</keyword>
  <keyword>naloxone</keyword>
  <keyword>opiate antagonist</keyword>
  <keyword>Sézary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

